Replies to post #235296 on Biotech Values

[Bickema]

We could but at lot of companies that sell off after approval have drugs with high list prices and reimbursement challenges.

Also hopefully after approval analysts will upgrade RVNC on M&A potential

[DewDiligence]

A selloff on approval is much less likely if the FDA label is favorable for RVNC.